GONO Foundation

GONO Foundation is a no-profit group of Italian Investigators committed to design & conduct of academic clinical trials in oncology

[Paolo Ciracì @p_ciracimd]

Our review and evidence-based algorithm on late-line treatment options for metastatic colorectal cancer patients

👉 https://t.co/YW8C83zqcd

@ChiaraCrem1 @VStudiale @carlottanto1 @NatRevClinOncol

[Arndt Vogel @ArndtVogel]

Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX HER2-negative GC/GEJ cancer
@TheLancetOncol
https://t.co/YwadIgg0rD
🔎ARMANI phs 3
👉mPFS 6·6 vs 3·5 mo
👉mOS 12·6 vs 10·4 mo
🧐switch maintenance could be an option for pts who are not eligible for ICI/🎯💊
@myESMO

[JCO Precision Oncology @JCOPO_ASCO]

KRASG12D-Mutated Metastatic #ColorectalCancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration: https://t.co/TQymOxNwIv @ChiaraCrem1, @FoundationGono #CRCSM

[Dario Trapani @darioT_]

The one & only one @Raffa_Casolino 🇺🇳 delivering the Keynote lecture at @AIOMtweet meeting in #Venice right now !

✨ An illuminating perspective on #Cancer control amidst Humanitarian Challenges ✨

@WHO #UHC
@AiomFondazione #LeGiornateDellEtica #SanServolo

[Erman Akkus @Erman_Akkus]

☢️Neoadjuvant CRT vs. ChT for initially unresectable locally advanced "Colon" cancer
@eClinicalMed

➡️45 patients
✅R0 resection: 80% vs. 20%, P < 0.001
✅3-year PFS: 76% vs. 45% , P = 0.049
✅3-year OS: 87.6% vs. 75% , P = 0.037
✅No differences in severe AEs

❗️Study was terminated prematurely because of R0 resection benefit of CRT

👉https://t.co/WqFpJLSwaN

@TheLancetOncol @TheLancet @LancetGastroHep @myESMO @OncoAlert #cancer #oncology #MedX

[Margherita Ambrosini @margheambro1]

How long should we treat our pts with MSI-H #mCRC with immune checkpoint inhibitors to preserve efficacy while optimizing toxicities and costs?
In our academic international study 🇮🇹🇫🇷🇺🇸 ETD within 1 year is not detrimental vs a longer duration. RCT are now warranted🔜

#ESMO24

[AIOM @AIOMtweet]

Un successo il Congresso Nazionale di AIOM Giovani 2024. Un grande lavoro del Working Group giovani.
#AIOM #CongressoNazionaleAIOMgiovani

[Margherita Ambrosini @margheambro1]

Promising combination for mCRC patients not fit for classical 1st line doublet chemo, personally I love this trial by @FoundationGono !

[Chiara Cremolini @ChiaraCrem1]

Best colleagues and friends ever! Ready for Atezo2!

[Chiara Cremolini @ChiaraCrem1]

Updated and OS results of Atezotribe by @FoundationGono 🇮🇹 Confirmed role of IS IC as biomarker of ICI sensitivity in pMMR mCRC. @carlottanto @FilippoPietran4 @lonardi_sara @LisaSalvy @IlBuonRossini https://t.co/aWspkIWanD

[Lorenzo Ferri MD PhD @LFerri123]

ESOPEC trial
It’s been a long 15 year journey, but so nice to see Docetaxel triplets come on top for the benefit of our patients!
CROSS just doesn’t work for GEA-EAC- radiation compensates for poor surgical control (trans-hiatal) and CM577 compensates for poor systemic control

[Sam Klempner @KlempnerSam]

Big year for gastroesophageal at #ASCO24 @ASCO
ESOPEC plenary
EA2174, ARMANI, and RENAISSANCE in the oral sessions. @KarynAGoodman @NataliyaUboha @FilippoPietran4 @eaonc @LFerri123 @FlorianLordick @YJanjigianMD @KoheiShitara @sara_lonardi1 @LizzySmyth1 @sundar__raghav

[ESMO Open @ESMO_Open]

What are the treatment patterns and outcomes for patients with BRAF-mutant mCRC after progression to encorafenib/cetiximab? In this article, Dr. Germani et al. report data from a large 🇮🇹 cohort, suggesting improved outcomes when TT is administered early. https://t.co/hsEW5hfRn2

[Federico Nichetti @fedenichetti]

Very important data in light of the ongoing PURITY study (NCT06037980) by @Mom_enji and @FoundationGono

[Nelson Dusetti 🇫🇷 🇦🇷 @NelsonDusetti]

AI-assisted transcriptomic signatures: a key step in personalizing pancreatic cancer treatment.
: https://t.co/mNVM7p6GNa

[Sam Klempner @KlempnerSam]

Happy to share latest international collaboration led by awesome @arnavmehta3 @AnMinae and others. @JeeyunM @CD_AACR @SU2Cscience

Early immune remodeling steers clinical response to frontline chemoimmunotherapy in advanced gastric. https://t.co/ctrOBa3hwq

[Melissa Lumish MD @LumishMelissa]

Early onset GI cancers will be highlighted at @ASCO #GI24

EO-EGC is rising along with CRC. Our results in @JNCI_Now show EO-EGC is:
⬆️gastric ⬆️diffuse type
🟰 stage/survival
Much still unknown
Fantastic collaboration @AndreaCercek @YJanjigianMD @SteveMaronMD @MSKCancerCenter

[Toni Choueiri, MD @DrChoueiri]

Paper 2:

Phase 3 trial of KRAS G12C inhibitor #sotorasib + #panitumumab demonstrated ⬆️ PFS in patients with chemo-refractory metastatic colorectal cancer.

@NEJM @mgfakih @FilippoPietran4

https://t.co/8WyOZcAh84

[Dario Trapani @darioT_]

🏆 @AIOMtweet @AiomFondazione

[Raffaella Casolino @Raffa_Casolino]

@pradeepbab @SirohiBhawna @SirohiBhawna, I worked with Venkata on a project and he was amazing! He coordinated 41 colleagues from India in the translation of patient information sheets for Biliary Cancers into 13 Indian languages. https://t.co/khwhOCfIlN